Future Perspectives on MRD Testing in Colorectal Cancer
The expert panel concludes its discussion with a focus on the future of MRD testing in colorectal cancer, highlighting the treatment landscape’s current strengths and challenges.
Video Player is loading.
EP: 1.Testing for MRD With ctDNA in Colorectal Cancer (CRC)
EP: 2.Platforms for Testing MRD in CRC
EP: 3.MRD Testing Practices in Colorectal Cancer
EP: 4.Patient Profile 1: A 50-Year-Old With Stage III Colorectal Cancer
EP: 5.Prospective Trial Data on MRD Testing in Early-Stage CRC
EP: 6.COSMOS-CRC-03: ctDNA and Recurrence in Colorectal Cancer
EP: 7.Patient Profile 2: A 39-Year-Old Woman with High-Risk Stage II CRC
EP: 8.DYNAMIC Trial: ctDNA Analysis Guiding Adjuvant Therapy in Early-Stage CRC
EP: 9.Colorectal Cancer: Key Updates from GALAXY At ASCO GI 2024
EP: 10.Rationale and Study Design of CIRCULATE-NORTH AMERICA in CRC
EP: 11.Initial Results from Phase 2 COBRA Study in Colorectal Cancer
EP: 12.Patient Profile 3: A 62-Year-Old Woman with Colon Cancer
EP: 13.The Study Design and Early Findings from the INTERCEPT Study in CRC
EP: 14.BESPOKE CRC: The Impact of ctDNA-Guided Therapy in CRC
Now Viewing
EP: 15.Future Perspectives on MRD Testing in Colorectal Cancer
Recent Videos
Optimizing Multidisciplinary Coordination for Successful Tarlatamab Implementation
Institutional Implementation: Setting Up Tarlatamab Administration
Choosing Between Tazemetostat and Zanubrutinib+Obinutuzumab: Key Factors & Patient Conversations
Expert Perspectives: Tazemetostat in R/R FL
Management Strategies for Localized Epithelioid Sarcoma: The Role of Neoadjuvant and Adjuvant Therapies
Key Takeaways and Future Perspectives: PSMA PET Imaging in Prostate Cancer
Evaluating the Role of Cu-PSMA PET Imaging in Prostate Cancer
A 62-Year-Old Woman With Epithelioid Sarcoma Treated With Tazemetostat
Emerging Clinical Trials: Novel Approaches in Second-Line ES-SCLC
Addressing Critical Unmet Needs in ES-SCLC Patient Management
Related Content
